Clinical Trials Browser

Phase 2 × Interventional × alectinib × Clear all

NCT04302025 2026-05-22

NAUTIKA1

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 2 Active not recruiting

920 enrolled 1 FDA

Other solid neoplasm

Solid Tumors

NCT02314481 2026-05-04

DARWINII

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Genomic Instability

NCT04116541 2026-04-24

MegaMOST

Phase 2 Recruiting

Neoplasm Metastasis

NCT03737994 2026-04-23

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

10 enrolled 17 charts

Lung Neoplasms

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT03445000 2025-04-08

ALERT-lung

Phase 2 Terminated

14 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Phase 2 Recruiting

Rare Tumor

NCT03944772 2025-01-30

ORCHARD

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2 Completed

Neoplasm Metastasis

NCT04632992 2025-01-08

MyTACTIC

Phase 2 Completed

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

NCT06692491 2024-11-18

SPRING

Phase 2 Not yet recruiting

Rare Tumour

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05015010 2024-08-09

ALNEO

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2 Completed

673 enrolled 22 charts

GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT05159245 2024-07-15

FINPROVE

Phase 2 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT04817956 2024-02-29

IMPRESS-N

Phase 2 Recruiting

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT05081674 2023-10-11

BLISS

Phase 2 Completed

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04644315 2023-08-07

ALpha-T

Phase 2 Terminated

1 enrolled 5 charts

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Renal Cell, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Melanoma, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT03779191 2023-07-06

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Phase 2 Completed

ALK Gene Rearrangement Positive

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03155009 2020-02-10

ATALK

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung